Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Sep;20(3):449-461.
doi: 10.1007/s42000-021-00289-z. Epub 2021 May 25.

Higher ovulation rate with letrozole as compared with clomiphene citrate in infertile women with polycystic ovary syndrome: a systematic review and meta-analysis

Affiliations
Meta-Analysis

Higher ovulation rate with letrozole as compared with clomiphene citrate in infertile women with polycystic ovary syndrome: a systematic review and meta-analysis

Alexandra P Tsiami et al. Hormones (Athens). 2021 Sep.

Abstract

Background: Polycystic ovary syndrome (PCOS) is a common cause of anovulatory infertility. According to the latest guidelines, letrozole should be considered as the first-line pharmacological treatment for women with WHO Group II anovulation or PCOS. However, the use of letrozole as an ovulation induction agent is not FDA or EMA approved, and its use is "off-label." The main concern with respect to letrozole regards its potential teratogenic effect on the fetus.

Purpose: To determine whether the probability of ovulation is higher with letrozole as compared to clomiphene citrate (CC) in anovulatory women with PCOS.

Methods: Randomized controlled trials (RCTs) comparing letrozole versus CC used for ovulation induction in infertile women with PCOS followed by timed intercourse (TI) or intrauterine insemination (IUI) were included in this meta-analysis. Primary outcome was ovulation. Secondary outcomes were live birth, clinical pregnancy, miscarriage, multiple pregnancy, and congenital anomalies. Subgroup analysis included patients who received letrozole or CC as first-line treatment, and patients with PCOS diagnosed according to the Rotterdam criteria.

Results: Twenty-six RCTs published between 2006 and 2019, involving 4168 patients who underwent 8310 cycles of ovulation induction, were included. The probability of ovulation was significantly higher in letrozole as compared to CC cycles (RR: 1.148, 95% CI: 1.077 to 1.223, 3017 women, 19 trials, I2: 47.7%, low-quality evidence).

Conclusion: A higher probability of ovulation is expected in infertile patients with PCOS treated with letrozole as compared to CC. The higher ovulation rate might have contributed to the higher clinical pregnancy and live birth rate. This finding is also true for patients who were administered letrozole as first-line treatment.

Trial registration: CRD42019125166.

Keywords: Clomiphene citrate; Letrozole; Meta-analyses; Ovulation; Ovulation induction therapy; PCOS; Systematic review.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352(12):1223–1236. https://doi.org/10.1056/NEJMra041536 - DOI - PubMed
    1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89(6):2745–2749. https://doi.org/10.1210/jc.2003-032046 - DOI - PubMed
    1. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO (2016) The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 31(12):2841–2855. https://doi.org/10.1093/humrep/dew218 - DOI - PubMed
    1. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2008) Consensus on infertility treatment related to polycystic ovary syndrome [published correction appears in Hum Reprod. 2008 Jun;23(6):1474]. Hum Reprod 23(3):462–477. https://doi.org/10.1093/humrep/dem426 - DOI
    1. ESHRE Capri Workshop Group (2012) Health and fertility in World Health Organization group 2 anovulatory women. Hum Reprod Update 18(5):586–599. https://doi.org/10.1093/humupd/dms019 - DOI

MeSH terms

LinkOut - more resources